Hendrik-Tobias Arkenau
Sarah Cannon Research Institute United Kingdom · Sarah Cannon Research Institute, UK · Sarah Cannon Research Institute, United Kingdom
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hendrik-Tobias Arkenau as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:01 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03101839 · Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid TumoursAstraZeneca · completed · Non-Small Cell Lung Cancer, Advanced Solid Tumours · principal investigator
- Ph1NCT02546661 · Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerAstraZeneca · active not recruiting · Muscle Invasive Bladder Cancer · principal investigator
- Ph1NCT02260661 · Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid TumoursAstraZeneca · completed · Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 11:01 UTC. The ranking covers the 200 most relevant of 73 PubMed records, and a shared surname and initials can bring in a namesake. All 73 on PubMed
- 1,198 citationsRCR 43.0
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.JAMA Oncol · 2017726 citationsRCR 22.6
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.Breast Cancer Res Treat · 2018630 citationsRCR 20.9
- 454 citationsRCR 23.9
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol · 2018419 citationsRCR 15.3
- 407 citationsRCR 15.2
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.J Clin Oncol · 2022291 citationsRCR 18.2
- 235 citationsRCR 5.7
- Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.Cancer Discov · 2022231 citationsRCR 15.5
- 225 citationsRCR 7.1